HF
TVRD

HRT Financial’s Tvardi Therapeutics TVRD Stock Holding History

HRT Financial’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,050
Closed -$47K – 5008
2025
Q4 		$47K Buy
+11,050
New +$99K ﹤0.01% 2886
2024
Q3 		– Sell
-4,547
Closed -$42K – 3299
2024
Q2 		$42K Buy
+4,547
New +$108K ﹤0.01% 1856
2024
Q1 		– Sell
-304
Closed -$8K – 3245
2023
Q4 		$8K Buy
+304
New +$12.6K ﹤0.01% 2100
2023
Q3 		– Sell
-4,814
Closed -$490K – 3251
2023
Q2 		$490K Buy
4,814
+3,006
+166% +$414K ﹤0.01% 1373
2023
Q1 		$319K Buy
+1,808
New +$605K ﹤0.01% 1680
2021
Q4 		– Sell
-993
Closed -$552K – 4248
2021
Q3 		$552K Buy
+993
New +$498K ﹤0.01% 1888
2020
Q4 		– Sell
-619
Closed -$283K – 2590
2020
Q3 		$283K Buy
+619
New +$360K 0.01% 1177

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

HRT Financial's TVRD Position: Q1 2026 in Review

HRT Financial sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 11,050 shares — an estimated $47K sold.

HRT Financial first reported a position in TVRD in Q3 2020 and held it in 7 quarters. The position peaked at $552K in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • HRT Financial reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 11,050 Tvardi Therapeutics shares in Q1 2026, an estimated $47K.
  • HRT Financial first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 7 quarters.
  • HRT Financial's Tvardi Therapeutics position peaked at $552K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.